

**Amendments to the Claims:**

Please cancel claims 1 and 10, as shown in the listing of claims that follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (canceled).

2. (Original) A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of the biologically active agent effective to treat the condition;

wherein the agent is selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;  
Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;  
Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;  
4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;  
Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;  
Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;  
Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;  
Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;

Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;  
Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;  
and pharmaceutically acceptable salts thereof.

3. (Original) The method of claim 2, wherein the agent is administered orally.
4. (Original) The method of claim 2, wherein the subject is a human.
5. (Original) The method of claim 4, wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.
6. (Original) The method of claim 2, wherein the condition is insulin resistance syndrome or Type II Diabetes.
7. (Original) The method of claim 2, wherein the condition is Type 1 Diabetes.
8. (Original) The method of claim 2, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.
9. (Original) A pharmaceutical composition for use in the treatment of a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis, arteriosclerosis and adapted for oral administration, comprising from one milligram to four hundred milligrams of biologically active agent selected from the group consisting of:  
4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;  
Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;

Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;  
4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;  
Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;  
Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;  
Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;  
Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;  
Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;  
Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;  
Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;  
and pharmaceutically acceptable salts thereof.

Claim 10 (canceled).